MiniMed Group, Inc. (MMED) is a publicly traded company in the Healthcare — Medical - Equipment & Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories.
Is MiniMed Group, Inc. stock overvalued or undervalued in 2026?
As of October 29, 2026, MiniMed Group, Inc. (MMED) trades at $19.25 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: MiniMed Group, Inc.
Market cap $5B · 52 weeks $11 – $24 (19 % below the high) · P/E no earnings · 2027 expected P/E 27.5× · Dividend none · Next earnings December 30, 2026 · expected EPS $0.12 · Closing price, Oct 29 · accounts published Sep 1.
- Valuation: EV/EBITDA 31.1× (no earnings).
- Business: ROIC 0 % (weak).
- Balance sheet: Net cash/EBITDA 3.1× (solid).
- Earnings: Next.
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 1 of 4 pass
- Gross margin 54.2 %, fails.
- ROIC 0.4 %, fails.
- R&D / Revenue 14.4 %, borderline.
- Net debt / EBITDA −3.1×, passes.
Against its peers (reference peers) — MiniMed Group, Inc.: P/E —; EV/EBITDA 31.1×; ROIC 0.4 %; $5.4B. Insulet Corp. (P/E 28.5×; EV/EBITDA 16.3×; ROIC 16.0 %; $10.6B), DexCom, Inc. (P/E 31.6×; EV/EBITDA 20.8×; ROIC 24.0 %; $30.2B), Medtronic Plc (P/E 23.9×; EV/EBITDA 14.5×; ROIC 6.4 %; $124B).
Profitability
| Return on Equity | -9.11% |
| Return on Invested Capital | 0.43% |
| Return on Assets | -6.97% |
| Gross Margin | 53.85% |
| Operating Margin | 0.53% |
| Net Margin | -10.21% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 1.81 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 2.83 |
Price Performance
| 1 month | -1.13% |
| 3 months | +6.65% |
Related companies: DXCM · PODD · MDT · 0J5Q.L
Explore sector: Healthcare · Medical - Equipment & Services
More sections of MMED: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks